263 related articles for article (PubMed ID: 30104348)
1. Altered conformational landscape and dimerization dependency underpins the activation of EGFR by
Ruan Z; Kannan N
Proc Natl Acad Sci U S A; 2018 Aug; 115(35):E8162-E8171. PubMed ID: 30104348
[TBL] [Abstract][Full Text] [Related]
2. EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios.
Kobayashi IS; Viray H; Rangachari D; Kobayashi SS; Costa DB
Cells; 2021 Dec; 10(12):. PubMed ID: 34944068
[No Abstract] [Full Text] [Related]
3. Computational and Experimental Characterization of Patient Derived Mutations Reveal an Unusual Mode of Regulatory Spine Assembly and Drug Sensitivity in EGFR Kinase.
Ruan Z; Katiyar S; Kannan N
Biochemistry; 2017 Jan; 56(1):22-32. PubMed ID: 27936599
[TBL] [Abstract][Full Text] [Related]
4. Structural characterization of EGFR exon 19 deletion mutation using molecular dynamics simulation.
Tamirat MZ; Koivu M; Elenius K; Johnson MS
PLoS One; 2019; 14(9):e0222814. PubMed ID: 31536605
[TBL] [Abstract][Full Text] [Related]
5. A Mechanistic Study of a Potent and Selective Epidermal Growth Factor Receptor Inhibitor against the L858R/T790M Resistance Mutation.
Akher FB; Farrokhzadeh A; Ravenscroft N; Kuttel MM
Biochemistry; 2019 Oct; 58(41):4246-4259. PubMed ID: 31589411
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic Insights into R776H Mediated Activation of Epidermal Growth Factor Receptor Kinase.
Ruan Z; Kannan N
Biochemistry; 2015 Jul; 54(27):4216-25. PubMed ID: 26101090
[TBL] [Abstract][Full Text] [Related]
7. Effects of oncogenic mutations on the conformational free-energy landscape of EGFR kinase.
Sutto L; Gervasio FL
Proc Natl Acad Sci U S A; 2013 Jun; 110(26):10616-21. PubMed ID: 23754386
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic mutations within the β3-αC loop of EGFR/ERBB2/BRAF/MAP2K1 predict response to therapies.
Zhang B; Chen Y; Dai P; Yu H; Ma J; Chen C; Zhang Y; Guan Y; Chen R; Liu T; Wang J; Yang L; Yi X; Xia X; Ma H
Mol Genet Genomic Med; 2020 Oct; 8(10):e1395. PubMed ID: 32757330
[TBL] [Abstract][Full Text] [Related]
9. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
[TBL] [Abstract][Full Text] [Related]
10. Mapping inhibitor response to the in-frame deletions, insertions and duplications of epidermal growth factor receptor (EGFR) in non-small cell lung cancer.
Ning J; Wu Q; Liu Z; Wang J; Lin X
J Recept Signal Transduct Res; 2016; 36(1):37-44. PubMed ID: 26096169
[TBL] [Abstract][Full Text] [Related]
11. Structural Differences between Wild-Type and Double Mutant EGFR Modulated by Third-Generation Kinase Inhibitors.
Lowder MA; Doerner AE; Schepartz A
J Am Chem Soc; 2015 May; 137(20):6456-9. PubMed ID: 25973741
[TBL] [Abstract][Full Text] [Related]
12. Molecular Dynamics Analysis of Binding of Kinase Inhibitors to WT EGFR and the T790M Mutant.
Park J; McDonald JJ; Petter RC; Houk KN
J Chem Theory Comput; 2016 Apr; 12(4):2066-78. PubMed ID: 27010480
[TBL] [Abstract][Full Text] [Related]
13. Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
Engel J; Smith S; Lategahn J; Tumbrink HL; Goebel L; Becker C; Hennes E; Keul M; Unger A; Müller H; Baumann M; Schultz-Fademrecht C; Günther G; Hengstler JG; Rauh D
J Med Chem; 2017 Sep; 60(18):7725-7744. PubMed ID: 28853575
[TBL] [Abstract][Full Text] [Related]
14. Structural Basis for the Functional Changes by EGFR Exon 20 Insertion Mutations.
Tamirat MZ; Kurppa KJ; Elenius K; Johnson MS
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33807850
[TBL] [Abstract][Full Text] [Related]
15. EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas.
Jorge SE; Lucena-Araujo AR; Yasuda H; Piotrowska Z; Oxnard GR; Rangachari D; Huberman MS; Sequist LV; Kobayashi SS; Costa DB
Clin Cancer Res; 2018 Dec; 24(24):6548-6555. PubMed ID: 30154228
[TBL] [Abstract][Full Text] [Related]
16. Molecular dynamics analysis of conserved hydrophobic and hydrophilic bond-interaction networks in ErbB family kinases.
Shih AJ; Telesco SE; Choi SH; Lemmon MA; Radhakrishnan R
Biochem J; 2011 Jun; 436(2):241-51. PubMed ID: 21426301
[TBL] [Abstract][Full Text] [Related]
17. Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors.
Juchum M; Günther M; Laufer SA
Drug Resist Updat; 2015 May; 20():12-28. PubMed ID: 26021435
[TBL] [Abstract][Full Text] [Related]
18. Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.
Kosaka T; Tanizaki J; Paranal RM; Endoh H; Lydon C; Capelletti M; Repellin CE; Choi J; Ogino A; Calles A; Ercan D; Redig AJ; Bahcall M; Oxnard GR; Eck MJ; Jänne PA
Cancer Res; 2017 May; 77(10):2712-2721. PubMed ID: 28363995
[TBL] [Abstract][Full Text] [Related]
19. Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer.
Tsigelny IF; Wheler JJ; Greenberg JP; Kouznetsova VL; Stewart DJ; Bazhenova L; Kurzrock R
Oncotarget; 2015 Mar; 6(8):6029-39. PubMed ID: 25760241
[TBL] [Abstract][Full Text] [Related]
20. Novel Selective and Potent EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer.
Li Y; Song Z; Jin Y; Tang Z; Kang J; Ma X
Molecules; 2016 Nov; 21(11):. PubMed ID: 27827863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
